Literature DB >> 19101954

Clinicopathological characteristics of intrahepatic cholangiocellular carcinoma presenting intrahepatic bile duct growth.

Yusuke Yamamoto1, Kazuaki Shimada, Yoshihiro Sakamoto, Minoru Esaki, Satoshi Nara, Daisuke Ban, Tomoo Kosuge, Hidenori Ojima.   

Abstract

BACKGROUND: Intrahepatic cholangiocellular carcinoma (ICC) presenting intraductal growth (IG) has distinct clinicopathological features with a favorable prognosis. The mass-forming (MF) plus IG type of ICC has not been previously investigated.
METHODS: One hundred forty-four patients with ICC underwent surgical resections and were classified according to the macroscopic type. The clinicopathological features of the IG type (n = 7) and MF plus IG type (n = 14) were retrospectively analyzed. The clinicopathological differences between the MF plus IG type and MF plus periductal infiltrating (PI) type (n = 37) were compared.
RESULTS: All of the patients with the IG type had no sign of recurrence and survived. The 5-year overall survival rates was significantly better in the MF plus IG type than in the MF plus PI type (41.3% vs. 13.3%, P = 0.034). Significant differences were recognized between the MF plus IG type and MF plus PI type, in terms of vascular resection (P = 0.030), mucosal extension (P = 0.006), and postoperative recurrence (P = 0.004).
CONCLUSIONS: The MF plus IG type had significantly better prognosis than the MF plus PI type. The IG type and MF plus IG type should be distinguished from other types even if hepatic hilar confluence is involved, because of the favorable outcome after surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19101954     DOI: 10.1002/jso.21214

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells.

Authors:  Pongsanat Pongcharoen; Artit Jinawath; Rutaiwan Tohtong
Journal:  Clin Exp Metastasis       Date:  2011-08-11       Impact factor: 5.150

2.  Late recurrence after resection of mass-forming intrahepatic cholangiocarcinoma: report of a case.

Authors:  Naoko Iwahashi Kondo; Ken Shirabe; Yohei Mano; Akinobu Taketomi; Tomoharu Yoshizumi; Toru Ikegami; Toshiro Masuda; Hiroto Kayashima; Naotaka Hashimoto; Kazutoyo Morita; Mizue Matsuo; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-09-14       Impact factor: 2.549

Review 3.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

4.  Improved Postoperative Survival for Intraductal-Growth Subtype of Intrahepatic Cholangiocarcinoma.

Authors:  Laura L Dover; Rojymon Jacob; Thomas N Wang; Joseph H Richardson; David T Redden; Peng Li; Derek A DuBay
Journal:  Am Surg       Date:  2016-11-01       Impact factor: 0.688

5.  The Evaluation of the Eighth Edition of the AJCC/UICC Staging System for Intrahepatic Cholangiocarcinoma: a Proposal of a Modified New Staging System.

Authors:  Yusuke Yamamoto; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Ryo Ashida; Katsuhisa Ohgi; Yasuni Nakanuma; Katsuhiko Uesaka
Journal:  J Gastrointest Surg       Date:  2019-04-22       Impact factor: 3.452

6.  Periductal infiltrating type of intrahepatic cholangiocarcinoma: a rare macroscopic type without any apparent mass.

Authors:  Masanori Uno; Kazuaki Shimada; Yusuke Yamamoto; Satoshi Nara; Minoru Esaki; Yoshihiro Sakamoto; Tomoo Kosuge; Hidenori Ojima
Journal:  Surg Today       Date:  2012-02-21       Impact factor: 2.549

7.  Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)".

Authors:  Yasuni Nakanuma; Yasunori Sato; Hidenori Ojima; Yae Kanai; Shinichi Aishima; Masakazu Yamamoto; Shun-ichi Ariizumi; Toru Furukawa; Hiroki Hayashi; Michiaki Unno; Tetsuo Ohta
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value.

Authors:  Yusuke Yamamoto; Teiichi Sugiura; Akiko Todaka; Yukiyasu Okamura; Takaaki Ito; Ryo Ashida; Yuko Kakuda; Yasuni Nakanuma; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

9.  Survival benefits of surgical resection in recurrent cholangiocarcinoma.

Authors:  Sun Choon Song; Jin Seok Heo; Dong Wook Choi; Seong Ho Choi; Woo Seok Kim; Min Jung Kim
Journal:  J Korean Surg Soc       Date:  2011-09-26

10.  Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan.

Authors:  Yoshihiro Sakamoto; Norihiro Kokudo; Yutaka Matsuyama; Michiie Sakamoto; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Yonson Ku; Masatoshi Kudo; Tadatoshi Takayama; Osamu Nakashima
Journal:  Cancer       Date:  2015-10-02       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.